FDA Warns of Increased Side Effects, Death Risk With Duvelisib
The FDA recommends that health care providers evaluate the risks and benefits of continuing Copiktra vs prescribing an alternative therapy.
Lymphoma News
LYMPHOMA ADVISOR
Lymphoma News
Zandelisib Displays “Exemplary” Efficacy in Relapsed/Refractory Follicular Lymphoma
Zandelisib produced a high overall response rate in a phase 2 trial of patients with relapsed/refractory follicular lymphoma.
Tisagenlecleucel Demonstrates Activity in Young Patients With R/R Non-Hodgkin Lymphoma
Tisagenlecleucel can produce responses in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma, a phase 2 study suggests.
In AIDS-Related Lymphoma, Outcomes Worse With Hypoalbuminemia
Among patients with AIDS-related lymphoma, hypoalbuminemia is linked to worse overall survival and progression-free survival.
Obinutuzumab Bests Rituximab in Previously Untreated Follicular Lymphoma
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.
Breyanzi Approved as Second-Line Treatment for Large B-Cell Lymphoma
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
Dual Effect Identified for Arsenic in Carcinogenesis
The arsenic level in drinking water was negatively associated with incidences of lymphoma and leukemia in men and women.
Prevalence of Cancer Among Pregnant Patients on the Rise
The prevalence of pregnancy with cancer increased 13.8% from 2016 to 2019.
Predicting Response to COVID-19 Vaccines in Patients With Hematologic Malignancies
Two treatment-related factors and the frequency of 6 cell types were associated with response to COVID-19 vaccination.
Federal Court Orders EPA to Reexamine Whether Roundup Causes Cancer
In its ruling, the court challenged the Trump-era finding that glyphosate was not a serious health risk and “not likely” to cause cancer.
Features of Fever of Unknown Origin Later Diagnosed as Lymphoma
Researchers sought to define clinical and prognostic features associated with fever of unknown origin in patients later diagnosed with lymphoma.
Acalabrutinib Is Highly Active Chemotherapy-Free Alternative for Marginal Zone Lymphoma
Among the TEAEs of clinical interest, the most frequent were infections, bleeding, cardiac events, anemia, and neutropenia and neutrophil count decrease.
Parsaclisib is a Potential Third-Line Therapy for Follicular Lymphoma
Parsaclisib is a potent, highly selective, next-generation phosphoinositide 3-kinase-delta (PI3K-delta) inhibitor.
Safety and Efficacy of Sugemalimab in Extranodal Natural Killer/T-Cell Lymphoma
Based on preliminary data from this study, sugemalimab was granted breakthrough therapy designation for adult patients with R/R ENKTL in 2021.
Brentuximab Vedotin Improves Outcomes in Pediatric High-Risk Classic Hodgkin Lymphoma
Results of a phase 3 trial suggest that brentuximab vedotin (Bv) with doxorubicin (A), vincristine (V), etoposide (E), prednisone (P), and cyclophosphamide (C) should be the new standard frontline therapy among youth with high-risk classic Hodgkin lymphoma (cHL).
Safety and Efficacy of a CD20-CD3-Specific Antibody Therapy for DLBCL
At a median follow-up of 12.6 months, the overall response rate was 51.6% and the CR rate was 39.4%.
Response to Axicabtagene Ciloleucel Superior to Standard Care in R/R Large B-Cell Lymphoma
Axi-cel improved event-free survival vs standard care in older patients with relapsed/refractory large B-cell lymphoma.
Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in Chronic Lymphocytic Leukemia
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
Bortezomib Provides No Benefit Over R-DHAP Alone in R/R DBLCL
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.
Orelabrutinib-Sintilimab Yields Responses in Primary CNS Lymphoma
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
Loading... 
Loading...